APASL 2023 | Prof. Jia Jidong: Latest Advances in Primary Biliary Cholangitis

APASL 2023 | Prof. Jia Jidong: Latest Advances in Primary Biliary Cholangitis

2024.01.06
Primary Biliary Cholangitis (PBC) is a chronic cholestatic liver disease mediated by autoimmunity, with its pathogenesis not yet fully understood. Traditionally, PBC was thought to predominantly affect Western populations, but in recent decades, there has been an increasing number of reported cases and published literature in the Asia-Pacific region, escalating the disease burden. In response, the Asia-Pacific Association for the Study of the Liver (APASL) released clinical guidelines for PBC last year to better guide clinical practice. Recently, at the 32nd APASL Annual Conference, Professor Jia Jidong from the Capital Medical University Affiliated Beijing Friendship Hospital, China, delivered an insightful academic lecture titled "Latest Advances in Primary Biliary Cholangitis".
Professor Xiaojun Huang Awarded International Collaboration Award by IACH

Professor Xiaojun Huang Awarded International Collaboration Award by IACH

2024.01.04
Renowned hematologist Professor Xiaojun Huang has been honored with the International Collaboration Award by the International Academy for Clinical Hematology (IACH). Prof. Huang, a pioneer in the successful implementation of haploidentical transplantation, has significantly contributed to the field of clinical hematology and played a crucial role in promoting global collaboration. The award ceremony took place on October 5, 2023, during the IACH annual meeting held in Paris. Professor Mohamad Mohty, the current president of IACH, praised Xiaojun Huang 's outstanding achievements and key contributions to international collaboration in his invitation and award speech.
Dr. Hongfei Zhang’s Team: Latest Stage Data Revealed for China’s “Sprout” Project, Aiding Clinical Cure for Children with Chronic Hepatitis B

Dr. Hongfei Zhang’s Team: Latest Stage Data Revealed for China’s “Sprout” Project, Aiding Clinical Cure for Children with Chronic Hepatitis B

2023.12.21
Chronic hepatitis B is the leading cause of liver disease in Chinese children, posing a serious threat to their health. The "Sprout" project is China's first large-scale real-world study focusing on antiviral treatment for chronic hepatitis B in children. Led by Dr. Hongfei Zhang's team, with Shenzhen Third People's Hospital as the main center, the project is a charitable initiative initiated by the Beijing Chen Jumei Foundation. On November 10, 2023, the first day of the 2023 American Association for the Study of Liver Diseases Annual Meeting (AASLD 2023), Dr. Hongfei Zhang's team from the Chen Jumei Medical Group presented the latest stage data of the "Sprout" project. The team's detailed introduction to the project and its progress is shared below.
AASLD 2023: 17 Must-See Studies

AASLD 2023: 17 Must-See Studies

2023.12.21
From November 10th to 14th, the annualHepatology Digest conference, the American Association for the Study of Liver Diseases (AASLD) 2023 held in Boston, USA. This event gathers the latest academic developments, clinical research findings, and major academic presentations in the field of liver disease. The following is a summary of 17 highly anticipated studies scheduled for presentation at the AASLD 2023 conference.
Headline: AASLD Hot Updates on MASLD from the 2023 Annual Meeting

Headline: AASLD Hot Updates on MASLD from the 2023 Annual Meeting

2023.12.21
On November 7, 2023, at 12:30 PM local time in Boston, the American Association for the Study of Liver Diseases (AASLD) held its sole pre-conference press briefing on Metabolic Associated Fatty Liver Disease (MASLD). Chaired by conference president Professor Norah Terrault, the event featured presentations by Professor Phuc Le of the Cleveland Clinic Lerner College of Medicine, who discussed his team's model predicting the changing prevalence of liver diseases in the U.S. until 2050. Dr. Zobair Younossi, the Global NASH Council Chairman, presented the latest findings on the correlation between food insecurity and MAFLD in American adolescents. Additionally, Dr. Rohit Loomba shared insights into the renaming of Non-Alcoholic Fatty Liver Disease (NAFLD) and the challenges associated with it.
AASLD Voice of China丨Dr. Fengmin Lu: A1762T/G1764A Mutation Promotes HBV Replication, HNF1α Holds Promise as a Novel Therapeutic Target

AASLD Voice of China丨Dr. Fengmin Lu: A1762T/G1764A Mutation Promotes HBV Replication, HNF1α Holds Promise as a Novel Therapeutic Target

2023.12.21
From November 10th to 14th, the annual highlight of hepatology, the American Association for the Study of Liver Diseases (AASLD) 2023, was grandly held in Boston, USA. With over 200 abstracts from Chinese experts and scholars selected for oral presentations or poster sessions, the achievements were commendable. Congratulations to all! Dr. Fengmin Lu's team from Peking University has three contributions to this event (1 oral presentation and 2 posters). Today, we'll share insights from one of the posters presented on the first day, November 10th, revealing the team's academic prowess. The research discovered that the A1762T/G1764A mutation, by affecting the HBV transcriptome, can promote HBV replication (Abstract Number: 1514-C).
AASLD Voice of China | Peking University Hepatology Institute Shines with 10 Achievements at AASLD 2023

AASLD Voice of China | Peking University Hepatology Institute Shines with 10 Achievements at AASLD 2023

2023.12.21
From November 10th to 14th, the annual international event in hepatology—the American Association for the Study of Liver Diseases (AASLD) 2023—was grandly held in Boston, USA. According to incomplete statistics, more than 200 abstracts from Chinese experts and scholars were selected for oral presentations or poster exchanges at this conference, achieving fruitful results. Congratulations are extended here! The Beijing University People's Hospital and Peking University Hepatology Institute team achieved 1 oral and 9 poster presentations on scientific research in the fields of hepatic encephalopathy, fatty liver, hepatitis C, hepatitis B, and liver cancer. Some research abstracts are shared below, and "Hepatology Digest" takes you to appreciate the team's excellence.